PMID- 16555324
OWN - NLM
STAT- MEDLINE
DCOM- 20060912
LR  - 20211203
IS  - 1527-6465 (Print)
IS  - 1527-6465 (Linking)
VI  - 12
IP  - 4
DP  - 2006 Apr
TI  - Influence of donor/recipient HLA-matching on outcome and recurrence of hepatitis 
      C after liver transplantation.
PG  - 644-51
AB  - The aim of this study was to analyze the effect of human leukocyte antigen (HLA) 
      matching on outcome, severity of recurrent hepatitis C and risk of rejection in 
      hepatitis C positive patients after liver transplantation (LT). In a 
      retrospective analysis, 165 liver transplants in patients positive for hepatitis 
      C virus (HCV) with complete donor/recipient HLA typing were reviewed for 
      recurrence of HCV and outcome. Follow-up ranged from 1 to 158 months (median, 
      74.5 months). Immunosuppression consisted of either cyclosporine-A- or 
      tacrolimus-based quadruple induction therapy including or an interleukin 
      2-receptor antagonist. Protocol liver biopsies were performed after 1, 3, 5, 7, 
      and 10 years and staged according to the Scheuer scoring system. The overall 1-, 
      5-, and 10-year graft survival figures were 81.8%, 69.11 and 62%, respectively. 
      There was no correlation in the study population between number of HLA mismatches 
      and graft survival. The number of rejection episodes increased significantly in 
      patients with more HLA mismatches (P < 0.05). In contrast to this, the fibrosis 
      progression was significantly faster in patients with 0-5 HLA mismatches compared 
      to patients with a complete HLA mismatch. In conclusion, HLA matching did not 
      influence graft survival in patients after LT for end-stage HCV infection, 
      however, despite less rejection episodes, the fibrosis progression increased in 
      patients with less HLA mismatches within the first year after LT.
CI  - Copyright 2006 AASLD
FAU - Langrehr, Jan Michael
AU  - Langrehr JM
AD  - Department of Surgery, Charite, Campus Virchow-Clinic, Humboldt University, 
      Berlin, Germany. jan.langrehr@charite.de
FAU - Puhl, Gero
AU  - Puhl G
FAU - Bahra, Marcus
AU  - Bahra M
FAU - Schmeding, Maximilian
AU  - Schmeding M
FAU - Spinelli, Antonino
AU  - Spinelli A
FAU - Berg, Thomas
AU  - Berg T
FAU - Schonemann, Constanze
AU  - Schonemann C
FAU - Krenn, Veit
AU  - Krenn V
FAU - Neuhaus, Peter
AU  - Neuhaus P
FAU - Neumann, Ulf Peter
AU  - Neumann UP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Liver Transpl
JT  - Liver transplantation : official publication of the American Association for the 
      Study of Liver Diseases and the International Liver Transplantation Society
JID - 100909185
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Brain Death
MH  - Follow-Up Studies
MH  - Graft Rejection/epidemiology/immunology
MH  - HLA Antigens/*immunology
MH  - Hepatitis C/*surgery
MH  - *Histocompatibility Testing
MH  - Humans
MH  - Immunosuppression Therapy/methods
MH  - Incidence
MH  - Liver Transplantation/*immunology/mortality
MH  - Recurrence
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Time Factors
MH  - *Tissue Donors
MH  - Treatment Failure
MH  - Treatment Outcome
EDAT- 2006/03/24 09:00
MHDA- 2006/09/13 09:00
CRDT- 2006/03/24 09:00
PHST- 2006/03/24 09:00 [pubmed]
PHST- 2006/09/13 09:00 [medline]
PHST- 2006/03/24 09:00 [entrez]
AID - 10.1002/lt.20648 [doi]
PST - ppublish
SO  - Liver Transpl. 2006 Apr;12(4):644-51. doi: 10.1002/lt.20648.